Screener
UroGen Pharma URGN Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 19) | ||
| Shareholders' deficit: | ||
| Ordinary shares, NIS 0.01 par value, 100,000,000 shares authorized at June 30, 2026 and December 31, 2025; 48,869,530 and 48,350,272 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 135 | 133 |
| Additional paid-in capital | 865,112 | 854,090 |
| Accumulated deficit | (997,641) | (959,716) |
| Accumulated other comprehensive income | (2) | 19 |
| Total shareholders' deficit | (132,396) | (105,474) |
| Total liabilities and shareholders' deficit | $252,590 | $200,455 |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's total equity?
- UroGen Pharma (URGN) reported total equity of -$132.4M in Q2 2026.
- How has UroGen Pharma's total equity changed year-over-year?
- UroGen Pharma's total equity decreased by 41.8% year-over-year, from -$93.38M to -$132.4M.
- What is the long-term trend for UroGen Pharma's total equity?
- Over 5 years (2020 to 2025), UroGen Pharma's total equity has grown at a 1.8% compound annual growth rate (CAGR), from $96.36M to -$105.47M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about UroGen Pharma's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude